icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
VCD (Bortezomib-cyclophosphamide, dexamethasone) is the current standard of care in Australia for the initial treatment of transplant eligible patients. Early trials of Venetoclax (V) has demonstrated a greater likelihood of disease response in some patients when used in combination with other therapies.

The primary aim of this trial is to determine the rate of complete response achieved by using Venetoclax and VCD. 

Recruitment updated as of April 2019. 

STUDY DESIGN

Multicentre, single arm, open label trial

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial, and studied for molecular biomarkers and disease response

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

TIME FRAME

2018 – 2021

SITE LOCATIONS

  • Alfred Hospital, VIC
  • St. George's Hospital, VIC
  • PeterMac, VIC
  • Austin Hospital, VIC
  • Royal Hobart Hospital, TAS

PARTICIPANTS

45 newly diagnosed patients with multiple myeloma, who will receive an Autologous Stem Cell Transplant (ASCT)

CURRENT ENROLMENT 

10

STATUS

Recruiting